Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment

Kedar, Rotem; Sabag, Ofra; Licthenstein, Michal; Lorberboum-Galski, Haya

doi:10.1002/cncr.27654

Cited by 8 publications

(1 citation statement)

References 42 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…sCD40L retains the trimeric structure of the full-length protein and its biological functions (37). The sCD40L was able to bind and internalize into B cells that expressed the CD40 receptor and specifically and efficiently induced apoptotic death (38). In the 1990, MacDonald et al (39) reported that trimeric sCD40L was able to inhibit apoptosis induced by the combination of agonists to a certain degree, but such rescue proved to be short-lived.…”

Section: Discussionmentioning

confidence: 99%

Soluble CD40 ligand inhibits the growth of non‑Hodgkin's lymphoma cells through the JNK signaling pathway

Feng

Wang

2020

Oncol Lett

View full text Add to dashboard Cite

The incidence of non-Hodgkin's lymphoma (NHL) has been increasing annually and has become a serious threat to human health. However, the pathogenesis of NHL remains unclear. The present study aimed to investigate the effect of soluble CD40 ligand (sCD40L) on NHL cells and its underlying mechanism. Cell Counting kit-8 assay and flow cytometry apoptosis experiments were conducted to investigate the effects of sCD40L on cell proliferation and apoptosis. Western blotting was performed to detect the protein expression levels of BAX, Bcl-2, ERK, p-ERK, JNK, p-JNK, p38, p-p38 and c-JUN. The results of the present study demonstrated that exogenous sCD40L significantly inhibited the proliferation and promoted the apoptosis of Raji and CA46 cells. Additionally, exogenous sCD40L promoted the apoptosis of lymphoma cells by activating the JNK signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%